Screener
Iovance Biotherapeutics, Inc. IOVA Operating Lease ROU Assets
Operating Lease ROU Assets at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total Current Assets | 464,257 | 442,689 |
| Property and equipment, net | 131,464 | 131,112 |
| Intangible assets, net | 263,894 | 279,324 |
| Operating lease right-of-use assets | 43,480 | 45,899 |
| Restricted cash | 6,005 | 5,980 |
| Long-term assets | 6,431 | 8,166 |
| Total Assets | $915,531 | $913,170 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY |
Item 1.Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Iovance Biotherapeutics, Inc.'s operating lease ROU assets?
- Iovance Biotherapeutics, Inc. (IOVA) reported operating lease ROU assets of $43.48M in Q2 2026.
- How has Iovance Biotherapeutics, Inc.'s operating lease ROU assets changed year-over-year?
- Iovance Biotherapeutics, Inc.'s operating lease ROU assets decreased by 13.0% year-over-year, from $49.95M to $43.48M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s operating lease ROU assets?
- Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s operating lease ROU assets has grown at a -3.5% compound annual growth rate (CAGR), from $54.76M to $45.9M.
- What does operating lease ROU assets mean?
- Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.
Ask your AI about Iovance Biotherapeutics, Inc.'s operating lease rou assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude